Clinical Pharmacokinetics and Pharmacodynamics of Warfarin - Clinical Pharmacokinetics
- ️Holford, Nicholas H. G.
- ️Fri Nov 09 2012
Aarons L, Chan E, Rowland M, Breckenridge A, Serlin M. Relationship between vitamin K-dependent clotting factors and warfarin anticoagulation at steady state. 3rd World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 27–August 1, 1986. Abstract no. 755, p. 55, 1986
Abbrecht PH, Huhta JC. Clinical application of a mathematical model for warfarin dosage determination. Bioengineering Program Report, University of Michigan, Ann Arbor, 1972
Abbrecht PH, O’Leary TJ, Behrendt DM. Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model. Clinical Pharmacology and Therapeutics 32: 129–136, 1982
Banfield C, O’Reilly R, Chan E, Rowland M. Phenylbutazonewarfarin interaction in man: further stereochemical and metabolic considerations. British Journal of Clinical Pharmacology 16: 669–675, 1983
Barr W. Presented at the ASHP Institute on Advanced Pharmacokinetics, Lexington, 1975
Beal S, Sheiner LB. The NONMEM system. American Statistician 34: 118, 1980
Bjornsson TD, Meffin PJ, Swezey SE, Blaschke TF. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. Journal of Pharmacology and Experimental Therapeutics 210: 316–321, 1979a
Bjornsson TD, Meffin PJ, Swezey SE, Blaschke TF. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. Journal of Pharmacology and Experimental Therapeutics 210: 323–326, 1979b
Breckenridge AM. Interindividual differences in the response to oral anticoagulants. Drugs 14: 367–375, 1977
Breckenridge AM, Orme M. Kinetics of warfarin absorption in man. Clinical Pharmacology and Therapeutics 14: 955–961, 1973
Breckenridge AM, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clinical Pharmacology and Therapeutics 15: 424–430, 1974
Carter BL, Reinders TP, Hamilton RA. Prediction of maintenance warfarin dosage from initial patient response. Drug Intelligence and Clinical Pharmacy 17: 23–26, 1983
Carter BL, Taylor JW, Reinders TP. Evaluation of two methods to predict maintenance warfarin. Drug Intelligence and Clinical Pharmacy 18: 510, 1984
Chan E, O’Reilly R, Rowland M. Stereochemical aspects of warfarin in man: a combined pharmacokinetic-pharmacodynamic model. British Journal of Clinical Pharmacology 19: 545P, 1984a
Chan E, Pegg M, Mackay AD, Cole RB, Rowland M. Stereochemical aspects of warfarin in patients receiving chronic therapy. British Journal of Clinical Pharmacology 19: 571P, 1984b
Choonara IA, Haynes BP, Cholertons, Breckenridge AM, Park BK, et al. Dissociation between vitamin K1 2,3-epoxide reductase and clotting factor synthesis with warfarin. 3rd World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 27–August 1, 1986. Abstract no. 756, p. 55, 1986
Chua LH, Dobrzanski S, Taylor P. Use of a warfarin dose prediction method. Journal of Clinical and Hospital Pharmacy 9: 253–256, 1984
Coleman R, Murray W, Hong R, Mitsouka C, Daschbach M, et al. Predicting response to warfarin. Thrombosis and Haemostasis 54: 79, 1985
Deykin D. Warfarin therapy. New England Journal of Medicine 283: 691–694, 1970a
Deykin D. ‘No-Load’ warfarin therapy. New England Journal of Medicine 283: 1346, 1970b
Dickson RB, King RW, Suthers MB. Warfarin: predicting maintenance doses. Australian Journal of Hospital Pharmacy 14: 30–31, 1984
Dobrzanski S. Predicting warfarin dosage. Journal of Clinical and Hospital Pharmacy 8: 247–250, 1983
Fasco MJ, Hildebrand EF, Suttie JW. Evidence that warfarin anticoagulant action involves two distinct reductase activities. Journal of Biological Chemistry 257: 11210–11212, 1982
Fasco MJ, Principe LM. R- and S-warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. Journal of Biological Chemistry 257: 4894–4901, 1982
Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Lancet 288: 1268–1270, 1984
Fischer AM, Dautzenberg N, Pertuiset D, Ganeval D, Houin G. Pharmacolinetics of warfarin in the nephrotic syndrome and effect on vitamin-K dependent clotting factors. Thrombosis and Haemostatis 54: 82, 1985
Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. New England Journal of Medicine 302: 1460–1466, 1980
Gordon BM, Wiser TH, Davis RJ. Warfarin maintenance-dose prediction based upon initial anticoagulant response. Clinical Pharmacy 3: 297–299, 1984
Gallus A, Jackaman J, Goodall K, Tillen J. The optimal duration of heparin treatment for venous thromboembolism. Thrombosis and Haemostasis 50: 52, 1983
Hignite C, Uetrecht J, Tschanz C, Azarnoff D. Kinetics of R and S warfarin enantiomers. Clinical Pharmacology and Therapeutics 28: 99–105, 1980
Holford NHG. Rational warfarin dosing: a pharmacokinetic-pharmacodynamic analysis. Abstract. Clinical Pharmacology and Therapeutics 39: 199, 1986
Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 6: 429–453, 1981
Hotraphinyo, K, Triggs EJ, Maybloom B, Maclaine-Cross A. Warfarin sodium: steady-state plasma levels and patient age. Clinical and Experimental Pharmacology and Physiology 5: 143–149, 1978
Husted S, Andreasen F. The influence of age on the response to anticoagulants. British Journal of Clinical Pharmacology 4: 559–565, 1977
Hull R, Hirsh J, Jay R, Carter C, England C, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New England Journal of Medicine 307: 1676–1681, 1982
International Committee for Standardisation in Haematology, International Committee on Thrombosis and Haemostasis. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thrombosis and Haemostasis 51: 155–156, 1985
Kelly JG, O’Malley K. Clinical pharmacokinetics of oral anticoagulants. Clinical Pharmacokinetics 4: 1–15, 1979
Kirking DM, Cohen IA, Shue ME, Hutchison TA. Relationship of age, weight and body surface area to warfarin maintenance dose requirements. Journal of Clinical and Hospital Pharmacy 10: 101–105, 1985
Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thrombosis and Haemostasis 49: 238–244, 1983
Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. I. New England Journal of Medicine 285: 487–498, 1971a
Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants. II. New England Journal of Medicine 285: 547–558, 1971b
Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, et al. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. Journal of Clinical Investigation 53: 1607–1617, 1974
Loeliger EA, van den Besselaar AMHP, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thrombosis and Haemostasis 53: 148–154, 1985
McGhee JR, Evans R, Wolfson PM, Dunlop S, Haspel L, et al. Predictability of the warfarin maintenance dose based on the initial response. Journal of the American Osteopathic Association 80: 335–339, 1981
Miller DR, Brown MA. Predicting warfarin maintenance dosage based on initial response. American Journal of Hospital Pharmacy 36: 1351–1355, 1979
Mungall D, Marshall J, Ludden TM, Hawkins DW, Crawford MH. Population kinetics of warfarin. 2nd World Conference on Clinical Pharmacology and Therapeutics, Washington DC, July 1983. Abstract No. 256, p. 44, 1983
Mungall DR. Predicting prothrombin time response to warfarin, Biotrack Information Bulletin, Biotrack, Inc., Sunnyvale, November 1984
Mungall D, Ludden TM, Marshall J, Crawford M, Hawkins D. Relationships between steady-state warfarin concentrations and anticoagulant effect. Clinical Pharmacokinetics 9 (Suppl. 1): 99–100, 1984a
Mungall D, Wong YY, Talbert RL, Crawford MH, Marshall J. Plasma protein binding of warfarin: methodological considerations. Journal of Pharmaceutical Sciences 73: 1000–1001, 1984b
Murray B, McWaters D, Coleman R, Ludden T, Mungall D. Pharmacodynamics of warfarin. Clinical Pharmacology and Therapeutics 37: 215, 1985
Nagashima R, O’Reilly RA, Levy G. Kinetics of pharmacological effects in man: the anticoagulant action of warfarin. Clinical Pharmacology 10: 22–35, 1969
O’Reilly RA, Aggeler PM. Determinants of the response to oral anticoagulant drugs in man. Pharmacological Reviews 22: 35–96, 1970
O’Reilly RA. Anticoagulant, antithrombotic, and thrombolytic drugs. In Gilman AG et al. (Eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th ed., Macmillan, New York, 1985
O’Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose. Circulation 28: 169–177, 1968
O’Reilly RA, Aggeler PM, Leong LS. Studies of the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man. Journal of Clinical Investigation 42: 1542–1551, 1963
O’Reilly RA, Trager WF, Motely CH, Howald W. Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. Journal of Clinical Investigation 65: 746–753, 1980
O’Reilly RA, Welling PG, Wagner JG. Pharmacokinetics of warfarin following intravenous administration to man. Thrombosis et Diathesis Haemorrhagica 25: 178–186, 1971
Park BK, Choonara IA, Haynes BP, Breckenridge AM, Mahia RG, et al. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxy coumarins. British Journal of Clinical Pharmacology 21: 289–294, 1986
Park BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. British Journal of Clinical Pharmacology 18: 655–662, 1984
Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In Evans et al. (Eds) Applied Pharmacokinetics, 2nd ed., Applied Therapeutics Inc., San Francisco, 1986
Peck CC, Beal SL, Sheiner LB, Nichols AI. Extended least squares nonlinear regression: a possible solution to the ‘Choice of Weights’ problem in analysis of individual pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 12: 545–558, 1984
Penner JA, Abbrecht PH. Lack of interaction between ibuprofen and warfarin. Current Therapeutic Research 18: 862–871, 1975
Peterson GM, McLean S, Jupe DML, Griffith RL, Roberts JR. A model which predicts maintenance warfarin dosage requirements from the response to a single dose. British Journal of Clinical Pharmacology 20: 177–178, 1985
Piroli RJ, Passananti GT, Shively CA, Vesell ES. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clinical Pharmacology and Therapeutics 30: 810–816, 1981
Porter RS, Lowenthal DT, Saris SD, Conry KC, Bies C, et al. Pharmacokinetic and pharmacodynamic analysis of warfarin in human subjects. Clinical Pharmacology and Therapeutics 37: 221, 1985
Powers WF, Abbrecht PH, Covell DG. Systems and microcomputer approach to anticoagulant therapy. IEEE Transactions on Biomedical Engineering BME-27: 520–523, 1980
Quick AJ. Discussion. In Flynn (Ed.) Blood clotting and allied problems. Transactions of the First Conference, pp. 85–88, Josiah Macy Jr. Foundation, New York, 1948
Routledge PA, Davies DM, Bell SM, Cavanagh JS, Rawlins MD. Predicting patient’s warfarin requirements. Lancet 2: 854–855, 1977
Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. European Journal of Clinical Pharmacology 15: 319–322, 1979a
Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. British Journal of Clinical Pharmacology 8: 243–247, 1979b
Sawyer WT. Predictability of warfarin dose requirements: Theoretical considerations. Journal of Pharmaceutical Sciences 68: 432–434, 1979
Sawyer WT. Warfarin. In Mungall (Ed.) Applied Clinical Pharmacokinetics, pp. 187–222, Raven Press, 1983
Sawyer WT, Finn AL. Digital computer-assisted warfarin therapy: Comparison of two models. Computers and Biomedical Research 12: 221–231, 1979
Sawyer WT, Raasch RH. Effect of heparin on prothrombin time. Clinical Pharmacy 3: 192–194, 1984
Schulman S, Lockner D, Bergstrom K, Blomback M. Intensive initial oral anticoagulation and shorter heparin treatment in deep vein thrombosis. Thrombosis and Haemostasis 52: 276–280, 1984
Sharma NK, Routledge PA, Rawlins MD, Davies DM. Predicting the dose of warfarin for therapeutic anticoagulation. Thrombosis and Haemostasis 47: 230–231, 1982
Sheiner LB. Computer-aided long term anticoagulation therapy. Computers and Biomedical Research 2: 519–536, 1969
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 9: 503–512, 1981
Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. Journal of Pharmaceutical Sciences 71: 1344–1348, 1982
Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. British Journal of Clinical Pharmacology 4: 315–320, 1977
Shepherd AMM, Wilson N, Stevenson IH. Warfarin sensitivity in the elderly. In Crooks & Stevenson (Eds) Drugs and the elderly, University Park Press, Baltimore, 1979
Slattery JT, Levy G, Jain A, McMahon FG. Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose of warfarin. Clinical Pharmacology and Therapeutics 25: 51–60, 1979a
Slattery JT, Levy G, Jain A, McMahon FG. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clinical Pharmacology and Therapeutics 25: 61–66, 1979b
Smith LH. Hemorrhagic diseases. In Page & Culver (Eds) Syllabus of laboratory examinations in clinical diagnosis, p. 199, Harvard University Press, Harvard, 1961
Spaethe R, Strauss J. The determination of the international sensitivity index (ISI) for conversion of prothrombin time (PT) into international normalized ratio (INR). Comparative studies with high and low factor sensitive thromboplastins. Thrombosis and Haemostasis 54: 80, 1985
Stirling Y, Howarth DJ, Stockley R, Bland R, Towler CM, et al. Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations. British Journal of Haematology 51: 37–45, 1982
Svec JM, Coleman RW, Mungall DR, Ludden TM. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. Therapeutic Drug Monitoring 7: 174–180, 1985
Theofanous TG, Barile RG. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. Journal of Pharmaceutical Sciences 62: 261–266, 1973
Thomas P, Fennerty A, Backhouse G, Bentley DP, Campbell IA, et al. Monitoring effects of oral anticoagulants during treatment with heparin. British Medical Journal 288: 191, 1984
Toon S, Hopkins KJ, Garstang FM, Digret B, Rowland M. The warfarin-cimetidine interaction: stereochemical considerations. British Journal of Clinical Pharmacology 21: 245–246, 1986
Udall JA. ‘No-Load’ warfarin therapy. New England Journal of Medicine 283: 1345–1346, 1970
van den Besselaar AMHP, Broekmans AW, Hoekstra-Schuman M, Jansen-Gruter R, Loeliger EA. Thromboplastin-dependent variation of the normalized prothrombin time (INR) in orally anticoagulated patients. Abstract. Thrombosis and Haemostasis 54: 80, 1985
Weiner B, Faraci PA, Fayad R, Swanson L. Warfarin dosage following prosthetic valve replacement: effect of smoking history. Drug Intelligence and Clinical Pharmacy 18: 904–906, 1984
Wessler S, Gitel SN. Warfarin: from bedside to bench. New England Journal of Medicine 311: 645–652, 1984
Whi Hon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 17: 1371–1377, 1978
Wiegman H, Vossepoel AM. A computer program for long term anticoagulation control. Computer Programs in Biomedicine 7: 71–84, 1977
Williams DB, Karl RC. A simple technic for predicting daily maintenance dose of warfarin. American Journal of Surgery 137: 572–576, 1979
Wingard LB, O’Reilly RA, Levy G. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Clinical Pharmacology and Therapeutics 23: 212–217, 1978
Yacobi A, Udall JA, Levy G. Intrasubject variation of warfarin binding to protein in serum of patients with cardiovascular disease. Clinical Pharmacology and Therapeutics 20: 300–303, 1976